The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies.
| Autor: | Kwantwi LB; Department of Pathology.; Beckman Research Institute, Duarte, California, USA., Rosen ST; Department of Hematology & Hematopoietic Cell Transplantation.; Beckman Research Institute, Duarte, California, USA., Querfeld C; Department of Pathology.; Department of Hematology & Hematopoietic Cell Transplantation.; Division of Dermatology, City of Hope Medical Center.; Beckman Research Institute, Duarte, California, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current opinion in oncology [Curr Opin Oncol] 2024 Sep 01; Vol. 36 (5), pp. 449-455. Date of Electronic Publication: 2024 Jun 19. |
| DOI: | 10.1097/CCO.0000000000001067 |
| Abstrakt: | Purpose of Review: In this review, we provide an overview of the current understanding of SLAM-family receptors in hematologic malignancies. We highlighted their contribution to the disease pathogenesis and targeting strategies to improve therapeutic outcomes. Recent Findings: Emerging studies have reported the tumor-promoting role of SLAM-family receptors in various hematologic malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, and multiple myeloma. Specifically, they regulate the interaction between malignant cells and the tumor microenvironment to promote apoptosis resistance, therapeutic resistance, impairment of antitumor and tumor progression. Summary: SLAM-family receptors promote the progression of hematologic malignancies by regulating the interaction between malignant cells and the tumor microenvironment. This provides the rationale that SLAM-targeted therapies are appealing strategies to enhance therapeutic outcomes in patients. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|